Viking Therapeutics Inc., the clinical-stage biotech that wowed investors this week with promising data from a mid-stage trial of its weight-loss drug, is bolstering its balance sheet by issuing new shares.
The company, whose stock VKTX has gained an impressive 129% in the week so far, priced a $550 million offering of 6.47 million shares at $85 a share late Wednesday, a discount over its closing price of $94.50.
Proceeds…
Master your money.
Subscribe to MarketWatch.
Get this article and all of MarketWatch.
Access from any device. Anywhere. Anytime.
Subscribe Now
Already a subscriber?
Log In
